Benito Casu

Nonanticoagulant Actions of Glycosaminoglycans

Job Harenberg, Benito Casu, B. Casu, 2011, Springer US.

Structural and conformational aspects of the anticoagulant and anti-thrombotic activity of heparin and dermatan sulfate.

Benito Casu, Marco Guerrini, G. Torri, 2004, Current pharmaceutical design.

Undersulfated, low-molecular-weight glycol-split heparin as an antiangiogenic VEGF antagonist.

Benito Casu, Marco Presta, Annamaria Naggi, 2004, Glycobiology.

Evidence for conformational equilibrium of the sulfated L-iduronate residue in heparin and in synthetic heparin mono- and oligo-saccharides: NMR and force-field studies

Benito Casu, Dino R. Ferro, Massimo Ragazzi, 1986 .

Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events

Robert Langer, Robert J Linhardt, Benito Casu, 2008, Nature Biotechnology.

Short heparin sequences spaced by glycol-split uronate residues are antagonists of fibroblast growth factor 2 and angiogenesis inhibitors.

Benito Casu, Marco Presta, Sergio Penco, 2002, Biochemistry.

Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate.

Benito Casu, Annamaria Naggi, Israel Vlodavsky, 2007, Current pharmaceutical design.